Q2FY27 record growth; FY27-28 capacity target of 16 billion units

Multi-year targets disclosedInvestor Communications View source PDF Explain this filing

MARKSANS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.4%Reaction day

₹314.40

prior close

₹313.70

announcement price

In-mkt

timing

Nifty Microcap 250market+2.2%-6.5% vs market

Pharmaceuticals peers, median of 173sector+0.8%-5.1% vs sector

On the reaction day the stock moved 6.5 pts less than Nifty Microcap 250 and 5.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

-0.1

15m

-0.7

30m

-3.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.4+2.2-6.5+0.8-5.1

Next day

-0.5+3.3-3.8+1.6-2.1

-3.2pendingpending+1.5-4.7

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 revenue rose 30.5% to ₹940 crore and net profit increased 44.8% to ₹143.5 crore. Operating profit rose 48.3% to ₹214 crore, with margin at 22.8%, above FY27 guidance of 20-21%. H1 operating cash flow was ₹322 crore, while cash stood at ₹1,124 crore. The FY27-28 roadmap targets Indian capacity of 16 billion units a year.

Likely market impact

Strong growth, wider margins and net cash support the stock, but Q2 net profit fell 10% QoQ and the US consumer environment remains soft.